Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Delaney Dennis R

Delaney Dennis R boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 25.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,470 shares of the pharmaceutical company's stock after buying an additional 1,305 shares during the quarter. Vertex Pharmaceuticals makes up 1.4% of Delaney Dennis R's investment portfolio, making the stock its 29th largest holding. Delaney Dennis R's holdings in Vertex Pharmaceuticals were worth $2,605,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of VRTX. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth approximately $30,000. Sugar Maple Asset Management LLC purchased a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $35,000. Golden State Wealth Management LLC bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $37,000. Truvestments Capital LLC increased its holdings in shares of Vertex Pharmaceuticals by 30.3% in the 4th quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after buying an additional 23 shares during the last quarter. Finally, ORG Partners LLC raised its position in shares of Vertex Pharmaceuticals by 108.2% during the 4th quarter. ORG Partners LLC now owns 102 shares of the pharmaceutical company's stock valued at $41,000 after buying an additional 53 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ:VRTX traded up $3.21 during trading on Friday, reaching $489.10. The stock had a trading volume of 1,205,462 shares, compared to its average volume of 1,328,900. The business has a fifty day moving average price of $486.09 and a 200-day moving average price of $465.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The stock has a market cap of $125.60 billion, a PE ratio of -222.32, a PEG ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. On average, equities analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

VRTX has been the topic of a number of analyst reports. Morgan Stanley lifted their price target on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the stock an "equal weight" rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. lowered their price target on shares of Vertex Pharmaceuticals from $503.00 to $500.00 and set an "overweight" rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $480.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 11th. Canaccord Genuity Group raised shares of Vertex Pharmaceuticals from a "sell" rating to a "hold" rating and upped their price objective for the company from $408.00 to $424.00 in a research note on Tuesday, February 11th. Finally, Scotiabank raised their target price on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research note on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $512.41.

Insider Activity

In related news, EVP David Altshuler sold 3,231 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the sale, the executive vice president now owns 26,512 shares in the company, valued at $13,256,000. This represents a 10.86 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Ourania Tatsis sold 244 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the transaction, the executive vice president now owns 67,695 shares of the company's stock, valued at $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 4,315 shares of company stock worth $2,121,012. 0.20% of the stock is currently owned by insiders.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.